Considering that Shen et al. reported increased LRP8 levels in patients with premature coronary artery disease [33], we could assume that the downregulation of LRP8 expression observed after treatment with PCSK9i in our study may have a beneficial effect on inhibiting the atherosclerotic process. The gene discussed is LRP8; the disease is coronary artery disorder.